BigOmics raises additional funding from a strategic investor
USI Startup Centre
24 March 2022
The Swiss biodata analytics startup closes Pre-Series A with additional investment from Eppendorf, a leading life science company that develops and sells instruments, consumables and services for laboratories worldwide. This capital injection brings the total amount raised so far to CHF 2.7M.
The Lugano-based startup with a vision to fast-track omics data analysis and reduce discovery time and R&D overhead costs in data-driven therapeutics and precision medicine demonstrated rapid growth in the past two years. Its self-service analytics platforms allow biologists to analyse omics data with maximum ease. BigOmics currently has six enterprise subscriptions with Biotech/Pharma companies and academic labs and received funding from several local and international investors.
The additional investment was initiated and carried out by the Eppendorf Innovation Company (EpIC), which serves as Eppendorf's interface for innovative startups. Founded in Hamburg (Germany) in 1945, Eppendorf develops products for liquid, sample and cell handling in laboratories worldwide. It currently has around subsidiaries in 30 countries and around 5,000 employees worldwide. As announced by Dr. Murodzhon Akhmedov and Dr. Ivo Kwee, BigOmics co-founders, the funds will be used to further develop their platforms, expand the team, and grow the market presence. From his side, the Co-CEO of Eppendorf, Peter Fruhstorfer, said that BigOmics and Eppendorf share a common goal of accelerating digitalisation in life science laboratories to make everyday research workflows simpler, safer, and more efficient.